Stephen Elliman

With over 13 years’ experience in stromal cell medicine, Steve Elliman is Chief Scientific Officer at Orbsen Therapeutics Ltd. Steve’s aim to develop effective cell therapies began during his PhD studies, where he worked to initially describe and define marrow derived mesenchymal stromal cells.

Steve’s research interest is in the field of mesenchymal stromal cell therapy, with a focus on defining and purifying therapeutic stromal cells using the proprietary marker CD362/Syndecan-2. At Orbsen, his group have demonstrated that therapeutic stromal cells can be purified from human marrow, umbilical cord and adipose tissue using antibodies to CD362. In addition, within the REDDSTAR and NEPHSTROM consortia, Orbsen are working to develop a closed automated GMP manufacturing process combining the MACSQuant Tyto for optimal CD362+ stromal cell isolation and the Terumo Quantum CES for cell expansion. Within the REDDSTAR and MERLIN FP7 programs, CD362+stromal cells have demonstrated efficacy in preclinical models of diabetic wounds, neuropathy, retinopathy, nephropathy and inflammatory liver disease. In collaboration with 4 EU GMP teams, 7 clinical teams and 15 leading academic collaborators, Orbsen will test the clinical safety of CD362+stromal cells in 4 EU funded clinical trials in 2016-17.